Alector, Inc. (NASDAQ:ALEC) Stock Short Interest Report for October

Posted by Geri Gentry on Nov 2nd, 2026

Alector, Inc. (NASDAQ:ALEC – Get Free Report) was the target of a large increase in short interest in October. As of October 15th, there was short interest totaling 10,254,239 shares, an increase of 66.8% from the September 30th total of 6,147,032 shares. Approximately 10.0% of the shares of the stock are short sold. Based on an average trading volume of 10,952,676 shares, the days-to-cover ratio is presently 0.9 days.

Wall Street Analyst Weigh In

ALEC has been the subject of a number of research reports. HC Wainwright raised their price objective on Alector from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. UBS Group reissued a “neutral” rating and issued a $1.50 price target on shares of Alector in a research report on Tuesday, October 6th. Morgan Stanley upped their price objective on shares of Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research note on Tuesday, October 6th. Finally, Weiss Ratings raised shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $4.62.

Get Our Latest Stock Analysis on ALEC

Insiders Place Their Bets

In other Alector news, CEO Arnon Rosenthal sold 72,606 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $193,131.96. Following the sale, the chief executive officer owned 2,294,600 shares in the company, valued at approximately $6,103,636. The trade was a 3.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Neil Berkley sold 29,251 shares of Alector stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the transaction, the chief financial officer directly owned 350,649 shares in the company, valued at approximately $932,726.34. This trade represents a 7.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 111,303 shares of company stock worth $295,633 over the last 90 days. Insiders own 8.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Merck & Co. Inc. acquired a new stake in Alector in the 2nd quarter worth approximately $7,126,896. Elmind Capital LP acquired a new position in Alector during the second quarter valued at approximately $1,809,000. BlackRock Inc. acquired a new position in Alector during the second quarter valued at approximately $15,774,000. Spruce Street Capital LP raised its position in shares of Alector by 87.9% in the first quarter. Spruce Street Capital LP now owns 2,101,068 shares of the company’s stock valued at $4,517,000 after purchasing an additional 983,082 shares during the period. Finally, Nantahala Capital Management LLC bought a new position in shares of Alector in the second quarter valued at approximately $8,679,399. 85.83% of the stock is owned by institutional investors.

Alector Stock Performance

Shares of ALEC opened at $2.21 on Monday. The company’s fifty day moving average is $2.08 and its 200-day moving average is $2.03. Alector has a 12 month low of $1.09 and a 12 month high of $2.76. The firm has a market cap of $246.77 million, a price-to-earnings ratio of -2.01 and a beta of 0.61. The company has a quick ratio of 5.26, a current ratio of 5.26 and a debt-to-equity ratio of 0.80.

Alector (NASDAQ:ALEC – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%. Equities analysts expect that Alector will post -0.47 EPS for the current fiscal year.

Alector Company Profile

(Get Free Report)

Alector, Inc (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research platform, known as immuno-neurology, is designed to use the body’s immune system to protect or restore the brain’s ability to maintain healthy neural connections.

Alector’s investigational pipeline has included antibody-based treatments for conditions such as frontotemporal dementia and Alzheimer’s disease. Its programs have targeted biological pathways associated with neurodegeneration, including progranulin and TREM2.